TITLE

Liver Resection after Downstaging Hepatocellular Carcinoma with Sorafenib

AUTHOR(S)
Barbier, L.; Muscari, F.; Le Guellec, S.; Pariente, A.; Otal, P.; Suc, B.
PUB. DATE
January 2011
SOURCE
International Journal of Hepatology;2011, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. Sorafenib is amolecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma in Child A patients. Aims. To address the question of sorafenib as neoadjuvant treatment. Methods. We describe the cases of 2 patients who had surgery after sorafenib. Results. The patients had a large hepatocellular carcinoma in the right liver with venous neoplastic thrombi (1 in the right portal branch, 1 in the right hepatic vein). After 9 months of sorafenib, reassessment showed that tumours had decreased in size with a necrotic component. A right hepatectomy with thrombectomy was performed, and histopathology showed 35% to 60% necrosis. One patient had a recurrence after 6 months and had another liver resection; they are both recurrence-free since then. Conclusion. Sorafenib can downstage hepatocellular carcinoma and thus could represent a bridge to surgery. It may be possible to select patients in good general condition with partial regression of the tumour with sorafenib for a treatment in a curative intent.
ACCESSION #
75197902

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics